Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Apogee Therapeutics Inc

APGE ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: HOLD

Last Close

$134.55

▲ +0.07%

Market Cap $10.18B · Vol 315.69K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.18B

Large Cap

Div Yield

N/A

EPS Growth

-6.50%

YoY

RSI (14)

57.63

Momentum

Beta

N/A

vs Market

52W High

$134.88

0.24% below

52W Low

$35.54

278.59% above

Volume

315.69K

Avg 396.40K

P/B

5.71

Price-to-book

ROE

-20.27%

Return on equity

Free Float

95.21%

Public shares

Shariah Compliance8 STANDARDS

✗ Apogee Therapeutics Inc (APGE) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does APGE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.22%

+0.44%

+60.35%

+98.51%

YTD

+78.26%

+252.96%

+505.54%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-255,843,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-20.27%
ROA · ROIC	-30.22% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.71
P/FCF	N/A
EPS Growth	-6.50%
Outstanding Shares	75.69M

Technical Indicators

50-Day SMA	$123.51
200-Day SMA	$86.93
RSI (14)	57.63
Beta	N/A
52-Week High	$134.88
52-Week Low	$35.54

Volume Today	315.69K
Avg Daily Volume (30D)	396.40K
Relative Volume	0.80x
Volatility (10D)	1.87
Volatility (30D)	2.24
Free Float	95.21%

Analyst Consensus

HOLD

Current Price $134.55

Mean Target $134.53

52W Low$35.54 52W High$134.88

Current

Target

$35.54 $134.88

Current Analyst target

-0.02% downside risk · 16 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01H51WZL7

ISINUS03770N1019

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.